Mouse tau still reduced by 84% six months after a single dose: AviadoBio announces new Alzheimer’s gene therapy data
AVB-406 aims to enable brain cells to keep reducing tau production, and the latest animal results offer clues about the durability of its effects. The company plans to begin a first-in-human trial in 2027, but there is no human evidence yet that lowering the protein can improve memory and daily functioning.